Form 4: NovoCure Director Jeryl Hilleman Receives Significant Equity Compensation Awards

NovoCure Ltd. Director Jeryl L. Hilleman was granted 11,215 restricted stock units and options to purchase 16,697 ordinary shares, effective June 4, 2025, as part of her compensation.

Summary

• Jeryl L. Hilleman, a Director of NovoCure Ltd. (NVCR), was granted equity awards as part of her compensation.
• On June 4, 2025, she acquired 11,215 Ordinary Shares in the form of Restricted Stock Units (RSUs). These RSUs were granted at a price of $0.00 and are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding the Company's 2026 annual general meeting of shareholders. Following this transaction, she beneficially owns 16,806 Ordinary Shares directly.
• Additionally, on June 4, 2025, she acquired 16,697 stock options to buy Ordinary Shares. These options have an exercise price of $16.72 and were granted at a price of $0.00. They will fully vest and become exercisable on the earlier of the first anniversary of the grant date or the day immediately preceding the Company's 2026 annual general meeting of shareholders, with an expiration date of June 4, 2035. Following this transaction, she beneficially owns 16,697 stock options directly.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation grant to a director, which is generally a positive sign of aligning interests and retaining talent, but it does not contain new operational or financial performance information.

Positives

• The grant of restricted stock units and stock options to a director aligns the director's interests with long-term shareholder value, as the awards vest over time and are tied to the company's stock performance.
• The awards are part of a standard compensation package, which is a common practice for attracting and retaining qualified board members.

Future Outlook

The vesting schedules for the granted restricted stock units and stock options extend into 2026, aligning the director's future compensation with the company's long-term performance and shareholder value.

Industry Context

Equity grants to directors are a common practice across industries, particularly in the biotechnology and medical device sectors like NovoCure, to incentivize long-term commitment and align leadership interests with company growth and shareholder returns.

Comparison to Industry Standards

• The grant of restricted stock units and stock options as part of director compensation is a standard practice in the U.S. public company landscape, comparable to compensation structures seen in other medical technology and pharmaceutical companies.
• The specific number of units and options granted would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this document does not provide such comparative data.

Stakeholder Impact

• Shareholders: The grant of equity awards to a director aligns their interests with shareholders, potentially encouraging decisions that enhance long-term stock value.

Next Steps

• The restricted stock units are scheduled to vest 100% on the earlier of the first anniversary of the grant date (June 4, 2026) or the day immediately preceding the Company's 2026 annual general meeting of shareholders.
• The stock options will fully vest and become exercisable on the earlier of the first anniversary of the grant date (June 4, 2026) or the day immediately preceding the Company's 2026 annual general meeting of shareholders.

Key Dates

Keywords

NovoCure, NVCR, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, Beneficial Ownership